The red blood cell as a novel regulator of human B-cell activation.


Journal

Immunology
ISSN: 1365-2567
Titre abrégé: Immunology
Pays: England
ID NLM: 0374672

Informations de publication

Date de publication:
08 2021
Historique:
revised: 12 02 2021
received: 19 05 2020
accepted: 01 03 2021
pubmed: 18 3 2021
medline: 5 10 2021
entrez: 17 3 2021
Statut: ppublish

Résumé

Non-immune cells are increasingly recognized as important in regulating immunity, but the role of red blood cells (RBC) remains relatively unexplored, despite their abundance in the circulation and a cell surface rich in potential ligands. Here, we determine whether RBC influence the activation state of human B cells. Separation of RBC from peripheral blood mononuclear cells increased B-cell expression of HLA-DR/DP/DQ, whilst reconstitution reduced the levels of B-cell activation markers HLA-DR/DP/DQ, CD86, CD69 and CD40, as well as decreasing proliferative responses and IgM secretion. Inhibition of B cells required contact with RBC and was abrogated by either removal of sialic acids from RBC or blocking the corresponding lectin receptor CD22 on B cells. Chronic lymphocytic leukaemia B cells express low levels of CD22 and were less susceptible to inhibition by RBC, which may contribute to their activated phenotype. Taken together, the results identify a novel mechanism that may suppress inappropriate responsiveness of healthy B cells whilst circulating in the bloodstream.

Identifiants

pubmed: 33728669
doi: 10.1111/imm.13327
pmc: PMC8274151
doi:

Substances chimiques

Antigens, CD 0
Antigens, Differentiation, T-Lymphocyte 0
CD40 Antigens 0
CD69 antigen 0
Immunoglobulin M 0
Lectins, C-Type 0
Sialic Acid Binding Ig-like Lectin 2 0
Sialic Acids 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

436-447

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 094847
Pays : United Kingdom

Informations de copyright

© 2021 The Authors. Immunology published by John Wiley & Sons Ltd.

Références

J Innate Immun. 2011;3(4):411-9
pubmed: 21178327
Cell Rep. 2013 Aug 15;4(3):566-77
pubmed: 23933259
Eur J Immunol. 1991 Dec;21(12):2951-62
pubmed: 1748148
Eur J Immunol. 2012 Dec;42(12):3212-22
pubmed: 22930244
Nat Commun. 2018 Aug 17;9(1):3287
pubmed: 30120234
J Biol Chem. 2004 Sep 24;279(39):40819-26
pubmed: 15226294
Biomed Res Int. 2015;2015:616834
pubmed: 25722984
J Proteome Res. 2017 Aug 4;16(8):2752-2761
pubmed: 28689405
Eur J Immunol. 1993 Jun;23(6):1358-63
pubmed: 7684686
Contemp Oncol (Pozn). 2014;18(1):29-33
pubmed: 24876818
J Exp Med. 2010 Jan 18;207(1):173-87
pubmed: 20038598
Blood. 2009 Oct 22;114(17):3668-76
pubmed: 19704115
Clin Hemorheol Microcirc. 2010;44(1):63-74
pubmed: 20134094
Science. 1990 Jun 15;248(4961):1373-9
pubmed: 2356469
Blood. 2005 Mar 1;105(5):2007-15
pubmed: 15284121
FEBS Lett. 2003 Jan 16;534(1-3):185-9
pubmed: 12527384
J Trauma. 2010 Aug;69(2):320-9
pubmed: 20699740
Blood. 2002 Jun 1;99(11):4087-93
pubmed: 12010811
J Immunol. 2000 Sep 15;165(6):2987-96
pubmed: 10975807
Transfusion. 2012 Apr;52(4):794-802
pubmed: 21981316
Blood. 2017 Jun 8;129(23):3100-3110
pubmed: 28416510
J Exp Med. 1997 Jun 16;185(12):2157-70
pubmed: 9182687
Age (Dordr). 2013 Oct;35(5):2009-24
pubmed: 23129025
Immunol Rev. 1988 Dec;106:149-80
pubmed: 3075588
Immunity. 2006 Jun;24(6):767-777
pubmed: 16782032
Eur J Immunol. 2002 Feb;32(2):348-55
pubmed: 11807774
Biomed Pharmacother. 1986;40(1):25-7
pubmed: 3708116
J Immunol. 2015 Jul 1;195(1):51-60
pubmed: 25987743
Nat Rev Immunol. 2008 Oct;8(10):764-75
pubmed: 18825130
PLoS One. 2019 Mar 20;14(3):e0213832
pubmed: 30893384
Virol J. 2010 Dec 23;7:370
pubmed: 21176236
Cancer Res. 2018 Mar 15;78(6):1379-1382
pubmed: 29440147
Nat Chem Biol. 2005 Jul;1(2):93-7
pubmed: 16408005
J Immunol. 2018 Feb 1;200(3):949-956
pubmed: 29288201
Glycobiology. 2014 Sep;24(9):807-17
pubmed: 25002414
Trends Mol Med. 2008 Aug;14(8):351-60
pubmed: 18606570
J Biol Chem. 2001 Jul 27;276(30):28106-12
pubmed: 11358961
J Immunol. 2015 Jun 15;194(12):5579-87
pubmed: 26048965
Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2500-5
pubmed: 19202057
Curr Biol. 1997 Feb 1;7(2):133-43
pubmed: 9016707

Auteurs

Charlotte S Lennon (CS)

Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK.

Huan Cao (H)

Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK.

Andrew M Hall (AM)

Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK.

Mark A Vickers (MA)

Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK.

Robert N Barker (RN)

Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH